Trials / Completed
CompletedNCT05157945
ALTO-300 in Depression (ALTO-300-004)
AN OPEN-LABEL STUDY OF ALTO-300 IN ADULTS WITH MAJOR DEPRESSIVE DISORDER
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 148 (actual)
- Sponsor
- Alto Neuroscience · Industry
- Sex
- All
- Age
- 18 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to collect biologically-based data for defining predictors and correlates of the effects of ALTO-300.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALTO-300 PO Tablet | One tablet daily |
Timeline
- Start date
- 2022-02-03
- Primary completion
- 2023-04-26
- Completion
- 2023-05-05
- First posted
- 2021-12-15
- Last updated
- 2024-04-26
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05157945. Inclusion in this directory is not an endorsement.